Merck Animal Health and Harrisvaccines, Inc., announced the
companies have entered into an agreement under which Merck Animal Health
will acquire Harrisvaccines, a privately-held company that develops,
manufactures and sells vaccines for food production and companion
animals.
Harrisvaccines offers innovative technology and an important portfolio
of vaccines, with a focus on production animals, an increasingly
important segment as consumer demand for protein continues to grow
worldwide. The company has a unique RNA Particle technology which
represents a breakthrough in vaccine development. It also has a highly
versatile production platform able to target a wide range of viruses and
bacteria. Pathogens are collected from a farm and specific genes are
sequenced and inserted into RNA particles, making safe, potent vaccines
able to provide herd-specific protection.